SurvodutidevsTesamorelin

Survodutide activates both GLP-1 and glucagon receptors with a carefully calibrated ratio of agonist activity at each target. The GLP-1 receptor engagement provides the established metabolic benefits of the incretin pathway — centrally mediated appetite suppression, glucose-dependent insulinotropic effects, and delayed gastric emptying — creating a foundation of weight loss and glycemic improvement.

The glucagon receptor component is particularly relevant to survodutide's development focus on MASH (metabolic dysfunction-associated steatohepatitis). Glucagon receptor activation in hepatocytes upregulates mitochondrial beta-oxidation of fatty acids, increases ketone body production, and stimulates amino acid catabolism. This hepatic metabolic shift directly addresses the pathological fat accumulation that defines MASH, reducing intrahepatic triglyceride content by mobilizing stored lipids for energy production rather than continued storage.

Beyond the liver, glucagon signaling increases whole-body energy expenditure through multiple mechanisms: enhanced thermogenesis in brown adipose tissue, increased futile cycling in metabolic pathways, and elevated basal metabolic rate. In clinical trials for MASH, survodutide has demonstrated significant reductions in liver fat content alongside substantial body weight loss. The dual mechanism addresses both the upstream cause (excess caloric intake) and the downstream pathology (hepatic steatosis and inflammation) of metabolic liver disease simultaneously.

Tesamorelin is a synthetic GHRH analogue consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This lipophilic modification enhances receptor binding affinity and provides modest resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, improving its pharmacokinetic profile compared to native GHRH.

Like other GHRH analogues, tesamorelin activates the GHRH receptor on pituitary somatotrophs via the Gs/cAMP/PKA pathway, stimulating endogenous GH synthesis and pulsatile secretion. The resulting increase in circulating GH and IGF-1 produces its primary therapeutic effect: targeted reduction of visceral adipose tissue (VAT). GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation.

The specificity of tesamorelin's effect on visceral rather than subcutaneous fat has been well-documented in clinical trials. Visceral adipose tissue is metabolically distinct — it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone. Clinical trials also showed improvements in hepatic steatosis (fatty liver) markers, triglyceride levels, and trunk fat distribution. It remains the only GHRH analogue with active FDA approval, specifically for HIV-associated lipodystrophy, where visceral fat accumulation is a common and distressing side effect of antiretroviral therapy.